Biocom California’s Post

Ensuring diversity in clinical trials is not only an equity issue but critical for generating accurate, reliable research results. Recently, CTTI’s Sabrena Mervin-Blake, Senior Project Manager and Lead for Diversity, Equity, and Inclusion, sat down with Xtalks to discuss key strategies for promoting inclusivity in clinical trials.  In the interview, Sabrena dives deep into the actionable steps organizations can take – from fostering partnerships with patient groups to holding leadership accountable for diversity efforts. Learn how CTTI is leading the charge to make clinical research more representative and equitable for all, and explore how your organization can be part of the change! https://bit.ly/3B7poz5

Who's behind the magic at Vitro? Our Meet the Team series kicks off with Michael Halling, our Founder & CEO. Each week, we'll be highlighting the individuals that make our company tick. We'll find out what they do, which parts they enjoy the most and some interesting personal facts! Check out below to find out more about Mike! #MeetTheTeam

Where does diversity, equity, and inclusion, truly stand in our industry? As we continue in this new age of life sciences, our goal is to move beyond buzzwords and truly comprehend the role of DE&I. And with over 80% of life science leaders saying DE&I is crucial to the success of a company, if you aren't already looking at your initiatives, now is the time to. We've put together a review filled with DE&I insights and best practices for implementing successful DE&I strategies—based on the real views and experiences of 120 employers across the biotech, pharmaceutical and medical device sectors. Download it below. #diversity #equity #inclusion #dei

At Target ALS, we believe that collaboration is the key to accelerating progress in ALS research. By bringing together researchers, clinicians, and industry leaders at our Annual Meeting meeting and in funded consortia, we foster an environment where knowledge is freely shared and innovative ideas flourish. Target ALS Board Member Chris Henderson talks about this collaborative spirit, which is essential for driving research from the laboratory to clinical trials, ensuring that promising discoveries can quickly translate into real-world treatments. Our approach not only speeds up the research process but also enhances the quality of potential therapies, bringing us closer to our goal of finding effective treatments for ALS. #TargetALS #ALSResearch #Collaboration #AcceleratingResearch #ClinicalTrials

I am excited to join the motivated and excellent team of employees, physician thought leaders, researchers, customers, investors, and strategic partner Stryker to help On Target Laboratories to accelerate Surgery 4.0 with our portfolio of advanced intraoperative imaging agents to target and illuminate various cancers during surgery, precision guided therapy. There is a huge unmet need in #digitalsurgery for more real time actionable information to help surgeons see cancer, remove it and improve cancer surgery procedures. We see the benefits to cancer patients being 1) better outcomes, 2) lower costs, and 3) more access to democratized care on a global basis. #digitalsurgery #molecularimaging #medtech #digitalhealth #surgery #cancertreatment #lungcancer #lungcancerawareness #cytalux Ben Lundgren Gwen Watanabe Bernie Haffey Purdue University Stryker Kevin Lobo Andres Rosales Olympus Corporation of the Americas Olympus Corporation Townsend Goddard Fritz French Andy Kessler Joe Mullings The Mullings Group

Bio€quity Europe is off to an outstanding start with the convergence of life sciences companies, investors, local and EU government, and those of us who support our clients in further support of advancing global public health! Our session today was moderated by Selina Koch, PhD , BioCentury Inc. and included Jennifer McMahon, Seroba, Edward Kliphuis, Sofinnova Partners, John W Cassidy, Kindred Capital VC, Florent Gros, Earlybird Venture Capital. I was thrilled to join such an outstanding group of investors to discuss the opportunities for AI to influence drug discovery, research and development! #BioEquityEurope

My experience nearly 25 years ago as a research coordinator for a clinical trial in lung cancer made me realize that patients deserve better, and I vowed to amplify patients’ voices and dedicated my career to improving drug development. In pharma, I had the privilege to work on the dawn of immunotherapy in lung cancer. With patients surviving longer with these therapies, I felt I was able to make a difference. When my son, Caffrey, was diagnosed with Duchenne muscular dystrophy, I was shocked that the standard of care today is still high dose steroids that do nothing to address the underlying genetic cause of the disease. I was even more disheartened when, after an exhaustive search of clinical trials, we found out that he was not eligible for a single one.  As a family, we felt marooned, alone, and really scared. I'm really at a loss to describe that sheer feeling of hopelessness and grief that comes when your child gets a catastrophic diagnosis. It can be all consuming and soul destroying. One of the first glimmers of hope during this time is when I found out about Alltrna. I immediately understood the potential of this platform and could see how Alltrna’s engineered tRNAs could be a lifeline for patients with thousands of genetic diseases and a lifeline for those families that love them. This was an opportunity for me to channel all my years in pharma and bring that drug development experience to those overlooked and underserved patient populations. In the last two decades, I can look back and feel like I've played a small but maybe a meaningful role in helping to advance the five year survival rates for many metastatic cancers and make those better. Can you imagine if in the next two decades, we can do the same for rare diseases? ➡️To do this, we need to first and foremost, lead with empathy, and always think about the patient at the center of what we do. ➡️We must drive innovation – don't wait for it to happen. We have to actively choose to make a difference in those bold choices that really make innovation matter. ➡️Take risks. Those safe bets aren't helping anyone. We have to take the risks to really make a difference for patients. ➡️Act with urgency – as if your kid's life depends on it. ➡️Really importantly, embrace who you are. ➡️At the end of the day, always, always, always remember patients deserve better. 

If you survived the toughest downturn in biotech history: Congratulations on a job well done.   But as we turn to 2025, the job will only get tougher for CEOs and boards. You don’t have the luxury of time. You must deliver again, even in uncertain markets.   Join BioCentury, BIA, and special guests for our second annual CEO and investor dialogue on the sidelines of the Jefferies London Healthcare Conference - Biotech's Next Challenge: Delivering the Story. Learn more and register: https://loom.ly/vIIBprM #drugdevelopment #investors #AI #pipelines

Unlock the full potential of your primary market research with a global pool of healthcare and life sciences insights. 🔬 Targeted Expertise: Zero in on the knowledge you need. Our AI-driven system connects you with top-tier professionals, ensuring high-impact insights for your projects. 🌍 Global Reach, Local Insight: We go beyond geographical boundaries to bring you seamless access to a world of hidden knowledge and niche expertise. 📈 Project Efficiency: Streamline your research process. Our platform is designed for ease, speed, and effectiveness, allowing you to focus on what matters - results. 💼 Proven Impact: Strategy Director Miguel Silva at OMass Therapeutics attests to the pivotal role Techspert played in their decision-making. Join the ranks of informed business leaders who trust our network. Take the first step towards smarter research at https://lnkd.in/eYQaX2-h

Join this incredible line up of panelists for a discussion around DEIB and its evolving philosophies. Register below! #diversity #DEIB #lifesciences #biospace